Raj Wadwa
Concepts (328)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Diabetes Mellitus, Type 1 | 130 | 2026 | 3890 | 8.130 |
Why?
| | Insulin Infusion Systems | 47 | 2026 | 477 | 5.120 |
Why?
| | Insulin | 53 | 2026 | 2507 | 3.890 |
Why?
| | Blood Glucose | 70 | 2026 | 2327 | 3.460 |
Why?
| | Hypoglycemic Agents | 53 | 2026 | 1387 | 3.310 |
Why?
| | Blood Glucose Self-Monitoring | 43 | 2025 | 699 | 2.720 |
Why?
| | Pancreas, Artificial | 18 | 2025 | 97 | 2.200 |
Why?
| | Hypoglycemia | 27 | 2025 | 477 | 2.090 |
Why?
| | Diabetic Angiopathies | 16 | 2019 | 263 | 1.540 |
Why?
| | Vascular Stiffness | 14 | 2019 | 486 | 1.440 |
Why?
| | Cardiovascular Diseases | 25 | 2019 | 2168 | 1.370 |
Why?
| | Adolescent | 102 | 2026 | 22428 | 1.230 |
Why?
| | Child | 77 | 2025 | 22633 | 1.010 |
Why?
| | Albuminuria | 4 | 2019 | 190 | 0.850 |
Why?
| | Telemedicine | 3 | 2022 | 945 | 0.820 |
Why?
| | Diabetes Mellitus, Type 2 | 11 | 2020 | 2583 | 0.790 |
Why?
| | Young Adult | 56 | 2026 | 14105 | 0.780 |
Why?
| | Hyperglycemia | 11 | 2022 | 375 | 0.760 |
Why?
| | Humans | 145 | 2026 | 144759 | 0.720 |
Why?
| | Patient Safety | 1 | 2025 | 347 | 0.710 |
Why?
| | Dyslipidemias | 4 | 2019 | 181 | 0.690 |
Why?
| | Male | 99 | 2026 | 72315 | 0.640 |
Why?
| | Female | 101 | 2026 | 78271 | 0.620 |
Why?
| | Biosensing Techniques | 2 | 2020 | 139 | 0.620 |
Why?
| | Uromodulin | 1 | 2019 | 22 | 0.590 |
Why?
| | Glycopeptides | 1 | 2019 | 44 | 0.590 |
Why?
| | Carotid Intima-Media Thickness | 3 | 2018 | 75 | 0.530 |
Why?
| | Insulin Lispro | 4 | 2022 | 42 | 0.520 |
Why?
| | Ketones | 2 | 2016 | 53 | 0.490 |
Why?
| | Diabetic Ketoacidosis | 6 | 2024 | 210 | 0.490 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 2 | 2014 | 439 | 0.480 |
Why?
| | Self-Management | 3 | 2024 | 201 | 0.470 |
Why?
| | Biomarkers | 10 | 2020 | 4271 | 0.470 |
Why?
| | Child, Preschool | 20 | 2024 | 11787 | 0.470 |
Why?
| | Autonomic Nervous System | 3 | 2013 | 79 | 0.460 |
Why?
| | Cholesterol | 6 | 2020 | 406 | 0.450 |
Why?
| | Adult | 57 | 2026 | 40449 | 0.440 |
Why?
| | Algorithms | 12 | 2024 | 1837 | 0.440 |
Why?
| | Diabetic Nephropathies | 5 | 2019 | 318 | 0.420 |
Why?
| | Remote Consultation | 1 | 2015 | 66 | 0.420 |
Why?
| | Patient Compliance | 2 | 2015 | 588 | 0.410 |
Why?
| | Calcinosis | 4 | 2014 | 234 | 0.400 |
Why?
| | Monitoring, Ambulatory | 4 | 2020 | 88 | 0.390 |
Why?
| | Cystatin C | 2 | 2015 | 65 | 0.380 |
Why?
| | Diagnostic Techniques, Cardiovascular | 2 | 2014 | 16 | 0.370 |
Why?
| | Patient Education as Topic | 4 | 2019 | 780 | 0.370 |
Why?
| | Case-Control Studies | 13 | 2020 | 3604 | 0.350 |
Why?
| | Triglycerides | 9 | 2022 | 520 | 0.350 |
Why?
| | Arteries | 2 | 2010 | 259 | 0.340 |
Why?
| | Glucagon | 3 | 2016 | 112 | 0.340 |
Why?
| | Insulin Aspart | 3 | 2022 | 30 | 0.330 |
Why?
| | Risk Factors | 27 | 2019 | 10779 | 0.330 |
Why?
| | Reproducibility of Results | 9 | 2024 | 3409 | 0.330 |
Why?
| | Graves Disease | 1 | 2010 | 30 | 0.320 |
Why?
| | Quality of Life | 6 | 2024 | 3185 | 0.310 |
Why?
| | Adipose Tissue | 3 | 2022 | 652 | 0.300 |
Why?
| | Body Mass Index | 11 | 2024 | 2438 | 0.300 |
Why?
| | Friedreich Ataxia | 1 | 2010 | 78 | 0.290 |
Why?
| | Cholesterol, LDL | 4 | 2014 | 358 | 0.290 |
Why?
| | Diabetes Complications | 2 | 2007 | 222 | 0.280 |
Why?
| | Glomerular Filtration Rate | 4 | 2019 | 760 | 0.280 |
Why?
| | Vascular Diseases | 2 | 2013 | 251 | 0.270 |
Why?
| | Psychometrics | 3 | 2021 | 734 | 0.270 |
Why?
| | Hyperlipidemias | 2 | 2007 | 122 | 0.270 |
Why?
| | Pulse Wave Analysis | 10 | 2019 | 266 | 0.270 |
Why?
| | Skiing | 2 | 2019 | 49 | 0.270 |
Why?
| | Middle Aged | 33 | 2024 | 35875 | 0.260 |
Why?
| | Practice Guidelines as Topic | 1 | 2015 | 1560 | 0.260 |
Why?
| | Cross-Over Studies | 8 | 2026 | 601 | 0.250 |
Why?
| | Insulin Resistance | 6 | 2019 | 1241 | 0.240 |
Why?
| | Calibration | 4 | 2019 | 151 | 0.240 |
Why?
| | Receptors, Interleukin-2 | 1 | 2005 | 64 | 0.230 |
Why?
| | Coronary Artery Disease | 3 | 2007 | 741 | 0.220 |
Why?
| | Apolipoproteins B | 1 | 2014 | 47 | 0.220 |
Why?
| | Blood Pressure | 7 | 2014 | 1769 | 0.220 |
Why?
| | Self Report | 2 | 2020 | 872 | 0.210 |
Why?
| | Exercise | 5 | 2019 | 2201 | 0.200 |
Why?
| | Heart Rate | 5 | 2019 | 855 | 0.200 |
Why?
| | Infusion Pumps, Implantable | 2 | 2020 | 26 | 0.200 |
Why?
| | Uric Acid | 2 | 2015 | 166 | 0.200 |
Why?
| | Adiponectin | 4 | 2012 | 244 | 0.200 |
Why?
| | Diabetes Mellitus | 4 | 2025 | 1098 | 0.190 |
Why?
| | Blood Vessels | 2 | 2018 | 171 | 0.190 |
Why?
| | Pilot Projects | 2 | 2020 | 1886 | 0.180 |
Why?
| | Diabetic Neuropathies | 3 | 2019 | 99 | 0.180 |
Why?
| | Cholesterol, HDL | 4 | 2014 | 200 | 0.180 |
Why?
| | Insulin, Regular, Human | 4 | 2023 | 47 | 0.180 |
Why?
| | Kidney | 3 | 2022 | 1495 | 0.180 |
Why?
| | Hypertension | 4 | 2019 | 1263 | 0.180 |
Why?
| | Adiposity | 2 | 2018 | 543 | 0.170 |
Why?
| | Computer Systems | 2 | 2018 | 56 | 0.170 |
Why?
| | Age Factors | 9 | 2016 | 3333 | 0.170 |
Why?
| | Technology | 1 | 2022 | 95 | 0.170 |
Why?
| | Lipids | 3 | 2014 | 710 | 0.170 |
Why?
| | Follow-Up Studies | 9 | 2023 | 5408 | 0.160 |
Why?
| | Glycosides | 1 | 2021 | 42 | 0.160 |
Why?
| | Guideline Adherence | 2 | 2015 | 589 | 0.160 |
Why?
| | Cohort Studies | 11 | 2017 | 5960 | 0.160 |
Why?
| | Adolescent Behavior | 2 | 2017 | 501 | 0.160 |
Why?
| | Treatment Outcome | 12 | 2025 | 11679 | 0.160 |
Why?
| | Microvessels | 2 | 2018 | 99 | 0.150 |
Why?
| | Carotid Arteries | 2 | 2013 | 207 | 0.150 |
Why?
| | Sports | 2 | 2019 | 211 | 0.150 |
Why?
| | Patient Dropouts | 1 | 2020 | 65 | 0.150 |
Why?
| | Evidence-Based Medicine | 2 | 2014 | 732 | 0.150 |
Why?
| | Coronary Vessels | 2 | 2014 | 251 | 0.150 |
Why?
| | Inpatients | 1 | 2024 | 545 | 0.150 |
Why?
| | Brachial Artery | 3 | 2016 | 206 | 0.150 |
Why?
| | Administration, Intranasal | 2 | 2016 | 93 | 0.150 |
Why?
| | Bacterial Vaccines | 1 | 1999 | 63 | 0.140 |
Why?
| | Prevalence | 6 | 2014 | 2834 | 0.140 |
Why?
| | Cardiotonic Agents | 1 | 2018 | 95 | 0.140 |
Why?
| | Pneumococcal Infections | 1 | 1999 | 103 | 0.140 |
Why?
| | Cross-Sectional Studies | 8 | 2024 | 5868 | 0.140 |
Why?
| | Biomedical Technology | 1 | 2018 | 49 | 0.140 |
Why?
| | Antihypertensive Agents | 3 | 2014 | 510 | 0.130 |
Why?
| | Transplantation Conditioning | 1 | 2019 | 186 | 0.130 |
Why?
| | Endocrinology | 1 | 2018 | 77 | 0.130 |
Why?
| | Ohio | 5 | 2015 | 145 | 0.130 |
Why?
| | Diabetic Cardiomyopathies | 2 | 2016 | 34 | 0.130 |
Why?
| | Adolescent Nutritional Physiological Phenomena | 1 | 2017 | 29 | 0.130 |
Why?
| | Streptococcus pneumoniae | 1 | 1999 | 177 | 0.130 |
Why?
| | Immunization | 1 | 1999 | 374 | 0.130 |
Why?
| | Infant | 7 | 2019 | 10034 | 0.130 |
Why?
| | Regression Analysis | 4 | 2014 | 1003 | 0.130 |
Why?
| | Hospitalization | 2 | 2024 | 2433 | 0.120 |
Why?
| | Proprotein Convertase 9 | 1 | 2017 | 87 | 0.120 |
Why?
| | Sex Factors | 5 | 2016 | 2112 | 0.120 |
Why?
| | Risk Assessment | 4 | 2014 | 3671 | 0.120 |
Why?
| | Caregivers | 1 | 2025 | 1049 | 0.120 |
Why?
| | Aorta | 1 | 2018 | 429 | 0.120 |
Why?
| | Wyoming | 1 | 2015 | 27 | 0.120 |
Why?
| | Coronary Disease | 3 | 2007 | 383 | 0.110 |
Why?
| | Meals | 3 | 2024 | 130 | 0.110 |
Why?
| | Aged | 12 | 2023 | 25913 | 0.110 |
Why?
| | Perception | 1 | 2018 | 377 | 0.110 |
Why?
| | Hormones | 1 | 2015 | 134 | 0.110 |
Why?
| | Periodontal Diseases | 1 | 2015 | 62 | 0.110 |
Why?
| | Delivery of Health Care | 1 | 2022 | 947 | 0.110 |
Why?
| | Colorado | 9 | 2017 | 4564 | 0.110 |
Why?
| | Automation | 2 | 2025 | 102 | 0.110 |
Why?
| | Metformin | 1 | 2018 | 318 | 0.110 |
Why?
| | Videoconferencing | 1 | 2015 | 66 | 0.110 |
Why?
| | Lipoproteins | 2 | 2022 | 169 | 0.110 |
Why?
| | Pediatric Obesity | 2 | 2019 | 637 | 0.110 |
Why?
| | Inflammation | 2 | 2018 | 2878 | 0.110 |
Why?
| | Surveys and Questionnaires | 7 | 2021 | 6048 | 0.110 |
Why?
| | Self Care | 2 | 2014 | 389 | 0.110 |
Why?
| | Vascular Calcification | 1 | 2016 | 110 | 0.110 |
Why?
| | History, 21st Century | 2 | 2025 | 219 | 0.110 |
Why?
| | Atherosclerosis | 3 | 2015 | 409 | 0.100 |
Why?
| | Patient Satisfaction | 1 | 2018 | 704 | 0.100 |
Why?
| | History, 20th Century | 2 | 2025 | 325 | 0.100 |
Why?
| | Ketosis | 1 | 2014 | 12 | 0.100 |
Why?
| | Creatinine | 2 | 2015 | 506 | 0.100 |
Why?
| | Dietary Fiber | 1 | 2014 | 59 | 0.100 |
Why?
| | Pandemics | 1 | 2022 | 1694 | 0.100 |
Why?
| | Goals | 1 | 2015 | 183 | 0.100 |
Why?
| | Monitoring, Physiologic | 1 | 2015 | 289 | 0.100 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2019 | 675 | 0.100 |
Why?
| | Bionics | 2 | 2022 | 14 | 0.090 |
Why?
| | Sleep | 2 | 2022 | 901 | 0.090 |
Why?
| | Parents | 4 | 2022 | 1403 | 0.090 |
Why?
| | Circadian Rhythm | 2 | 2015 | 514 | 0.090 |
Why?
| | Pediatrics | 2 | 2018 | 1114 | 0.090 |
Why?
| | Acetaminophen | 1 | 2015 | 264 | 0.090 |
Why?
| | Randomized Controlled Trials as Topic | 3 | 2023 | 1720 | 0.090 |
Why?
| | Feasibility Studies | 3 | 2026 | 1095 | 0.090 |
Why?
| | Femoral Artery | 1 | 2013 | 190 | 0.090 |
Why?
| | Prognosis | 6 | 2020 | 4282 | 0.090 |
Why?
| | Longitudinal Studies | 6 | 2016 | 2947 | 0.090 |
Why?
| | Vitamin D Deficiency | 1 | 2013 | 186 | 0.090 |
Why?
| | Obesity | 3 | 2020 | 3077 | 0.090 |
Why?
| | Registries | 3 | 2020 | 2385 | 0.090 |
Why?
| | Kidney Function Tests | 1 | 2011 | 157 | 0.080 |
Why?
| | Injections, Subcutaneous | 2 | 2020 | 164 | 0.080 |
Why?
| | Vitamin D | 1 | 2013 | 400 | 0.080 |
Why?
| | Precision Medicine | 1 | 2014 | 457 | 0.080 |
Why?
| | Thyroidectomy | 1 | 2010 | 91 | 0.080 |
Why?
| | Hypolipidemic Agents | 2 | 2008 | 88 | 0.080 |
Why?
| | Glycosuria | 1 | 2009 | 10 | 0.080 |
Why?
| | Blood Flow Velocity | 2 | 2010 | 413 | 0.080 |
Why?
| | Infant, Newborn | 4 | 2019 | 6429 | 0.070 |
Why?
| | Outpatients | 3 | 2021 | 442 | 0.070 |
Why?
| | Prospective Studies | 4 | 2025 | 7990 | 0.070 |
Why?
| | Consensus | 2 | 2022 | 488 | 0.070 |
Why?
| | United States | 8 | 2020 | 15966 | 0.070 |
Why?
| | Double-Blind Method | 3 | 2021 | 2029 | 0.070 |
Why?
| | Combined Modality Therapy | 3 | 2017 | 1266 | 0.070 |
Why?
| | Angiotensin II Type 2 Receptor Blockers | 1 | 2007 | 7 | 0.070 |
Why?
| | Age Distribution | 2 | 2006 | 403 | 0.070 |
Why?
| | Life Style | 2 | 2008 | 479 | 0.070 |
Why?
| | Equipment Design | 2 | 2019 | 530 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2007 | 112 | 0.060 |
Why?
| | Health Promotion | 1 | 2014 | 774 | 0.060 |
Why?
| | Mobile Applications | 2 | 2020 | 196 | 0.060 |
Why?
| | Clinical Trials as Topic | 1 | 2012 | 1053 | 0.060 |
Why?
| | Smoking | 1 | 2014 | 1472 | 0.060 |
Why?
| | Cold Temperature | 2 | 2019 | 209 | 0.060 |
Why?
| | Polymorphism, Genetic | 2 | 2007 | 612 | 0.060 |
Why?
| | Fetal Distress | 1 | 2006 | 14 | 0.060 |
Why?
| | Disease Progression | 5 | 2018 | 2847 | 0.060 |
Why?
| | Renin-Angiotensin System | 1 | 2007 | 78 | 0.060 |
Why?
| | Apolipoproteins A | 1 | 2006 | 18 | 0.060 |
Why?
| | Catheter Ablation | 1 | 2010 | 353 | 0.060 |
Why?
| | Angiotensin-Converting Enzyme Inhibitors | 1 | 2007 | 221 | 0.060 |
Why?
| | Time Factors | 3 | 2014 | 7173 | 0.060 |
Why?
| | Diagnosis, Differential | 1 | 2010 | 1489 | 0.060 |
Why?
| | Pregnancy Complications, Cardiovascular | 1 | 2006 | 83 | 0.060 |
Why?
| | Postprandial Period | 2 | 2018 | 118 | 0.060 |
Why?
| | Hypertrophy | 2 | 2016 | 127 | 0.060 |
Why?
| | Family Health | 1 | 2006 | 191 | 0.060 |
Why?
| | Seasons | 2 | 2019 | 556 | 0.060 |
Why?
| | Linear Models | 3 | 2014 | 854 | 0.060 |
Why?
| | Infant, Newborn, Diseases | 1 | 2006 | 113 | 0.050 |
Why?
| | Radiography | 1 | 2007 | 844 | 0.050 |
Why?
| | Pregnancy in Diabetics | 1 | 2006 | 121 | 0.050 |
Why?
| | Glucose Intolerance | 1 | 2005 | 142 | 0.050 |
Why?
| | Cotinine | 1 | 2004 | 79 | 0.050 |
Why?
| | Sex Distribution | 1 | 2005 | 386 | 0.050 |
Why?
| | Hair | 1 | 2004 | 88 | 0.050 |
Why?
| | Quality-Adjusted Life Years | 1 | 2024 | 121 | 0.050 |
Why?
| | Inflammation Mediators | 1 | 2006 | 509 | 0.050 |
Why?
| | Rats | 1 | 2012 | 5597 | 0.050 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2005 | 381 | 0.050 |
Why?
| | Chitinase-3-Like Protein 1 | 1 | 2022 | 18 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1256 | 0.050 |
Why?
| | Hemodynamics | 2 | 2022 | 1121 | 0.050 |
Why?
| | Glucose | 2 | 2021 | 1047 | 0.050 |
Why?
| | Incidence | 3 | 2014 | 2879 | 0.050 |
Why?
| | Retrospective Studies | 6 | 2024 | 17066 | 0.050 |
Why?
| | Seizures | 1 | 2006 | 460 | 0.050 |
Why?
| | Predictive Value of Tests | 3 | 2015 | 2115 | 0.050 |
Why?
| | Societies, Medical | 2 | 2018 | 887 | 0.050 |
Why?
| | Tobacco Smoke Pollution | 1 | 2004 | 233 | 0.040 |
Why?
| | Reference Values | 2 | 2018 | 797 | 0.040 |
Why?
| | Motor Activity | 2 | 2018 | 721 | 0.040 |
Why?
| | Insulin-Secreting Cells | 1 | 2005 | 388 | 0.040 |
Why?
| | Cost-Benefit Analysis | 1 | 2024 | 634 | 0.040 |
Why?
| | Sitosterols | 1 | 2020 | 2 | 0.040 |
Why?
| | Phytosterols | 1 | 2020 | 12 | 0.040 |
Why?
| | Logistic Models | 1 | 2005 | 2117 | 0.040 |
Why?
| | Intention to Treat Analysis | 1 | 2020 | 80 | 0.040 |
Why?
| | Behavior Therapy | 1 | 2023 | 299 | 0.040 |
Why?
| | Social Conditions | 1 | 2019 | 13 | 0.040 |
Why?
| | Pancreas | 1 | 2022 | 341 | 0.040 |
Why?
| | Environmental Exposure | 1 | 2004 | 588 | 0.040 |
Why?
| | India | 1 | 2020 | 218 | 0.040 |
Why?
| | Autonomic Nervous System Diseases | 1 | 2019 | 34 | 0.040 |
Why?
| | Factor Analysis, Statistical | 1 | 2020 | 293 | 0.040 |
Why?
| | Vaccines, Conjugate | 1 | 1999 | 60 | 0.040 |
Why?
| | Anthropometry | 1 | 2019 | 200 | 0.040 |
Why?
| | Personal Satisfaction | 1 | 2021 | 222 | 0.040 |
Why?
| | Fear | 1 | 2022 | 366 | 0.040 |
Why?
| | Waist Circumference | 1 | 2018 | 139 | 0.030 |
Why?
| | International Cooperation | 1 | 2018 | 198 | 0.030 |
Why?
| | Smartphone | 1 | 2019 | 102 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2021 | 1047 | 0.030 |
Why?
| | Interdisciplinary Communication | 1 | 2019 | 197 | 0.030 |
Why?
| | Virginia | 1 | 2017 | 55 | 0.030 |
Why?
| | Accelerometry | 1 | 2018 | 119 | 0.030 |
Why?
| | Sex Characteristics | 2 | 2017 | 790 | 0.030 |
Why?
| | Age of Onset | 1 | 2018 | 551 | 0.030 |
Why?
| | Magnetic Resonance Angiography | 1 | 2018 | 251 | 0.030 |
Why?
| | Child Nutritional Physiological Phenomena | 1 | 2017 | 106 | 0.030 |
Why?
| | Ambulatory Care Facilities | 1 | 2019 | 265 | 0.030 |
Why?
| | Vascular Capacitance | 1 | 2016 | 4 | 0.030 |
Why?
| | Mass Spectrometry | 1 | 2019 | 750 | 0.030 |
Why?
| | Powders | 1 | 2016 | 44 | 0.030 |
Why?
| | Food Preferences | 1 | 2017 | 126 | 0.030 |
Why?
| | Equipment Failure | 1 | 2016 | 115 | 0.030 |
Why?
| | Injections, Intramuscular | 1 | 2016 | 141 | 0.030 |
Why?
| | Nausea | 1 | 2016 | 111 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2024 | 1152 | 0.030 |
Why?
| | Family | 1 | 2020 | 679 | 0.030 |
Why?
| | Ankle Brachial Index | 1 | 2015 | 41 | 0.030 |
Why?
| | Child Behavior | 1 | 2017 | 236 | 0.030 |
Why?
| | Early Diagnosis | 1 | 2016 | 249 | 0.030 |
Why?
| | Drug Delivery Systems | 1 | 2018 | 380 | 0.030 |
Why?
| | International Agencies | 1 | 2014 | 30 | 0.030 |
Why?
| | Magnetic Resonance Imaging | 1 | 2007 | 3863 | 0.030 |
Why?
| | Apolipoproteins | 1 | 2014 | 38 | 0.030 |
Why?
| | United States Food and Drug Administration | 1 | 2015 | 203 | 0.030 |
Why?
| | Program Evaluation | 1 | 2019 | 948 | 0.030 |
Why?
| | Adolescent Medicine | 1 | 2014 | 26 | 0.030 |
Why?
| | Societies, Scientific | 1 | 2014 | 49 | 0.030 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2015 | 561 | 0.030 |
Why?
| | Pressure | 1 | 2014 | 225 | 0.030 |
Why?
| | Nutrition Policy | 1 | 2014 | 58 | 0.030 |
Why?
| | Activities of Daily Living | 1 | 2017 | 441 | 0.020 |
Why?
| | China | 1 | 2014 | 269 | 0.020 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 257 | 0.020 |
Why?
| | Risk | 1 | 2016 | 911 | 0.020 |
Why?
| | Patient Care Team | 1 | 2019 | 689 | 0.020 |
Why?
| | Primary Prevention | 1 | 2015 | 220 | 0.020 |
Why?
| | Fibrinogen | 1 | 2014 | 177 | 0.020 |
Why?
| | Up-Regulation | 1 | 2015 | 851 | 0.020 |
Why?
| | Feeding Behavior | 1 | 2018 | 684 | 0.020 |
Why?
| | American Heart Association | 1 | 2014 | 350 | 0.020 |
Why?
| | Diabetic Retinopathy | 1 | 2014 | 208 | 0.020 |
Why?
| | Genotype | 2 | 2007 | 1833 | 0.020 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2016 | 2027 | 0.020 |
Why?
| | Quality Improvement | 1 | 2019 | 1289 | 0.020 |
Why?
| | Pulsatile Flow | 1 | 2010 | 55 | 0.020 |
Why?
| | Animals | 1 | 2012 | 38058 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2018 | 1356 | 0.020 |
Why?
| | Elasticity | 1 | 2010 | 184 | 0.020 |
Why?
| | Arm | 1 | 2010 | 109 | 0.020 |
Why?
| | South Carolina | 1 | 2008 | 48 | 0.020 |
Why?
| | Lipoproteins, HDL | 1 | 2008 | 101 | 0.020 |
Why?
| | Nutrition Therapy | 1 | 2008 | 37 | 0.020 |
Why?
| | Lipoproteins, LDL | 1 | 2008 | 119 | 0.020 |
Why?
| | Models, Biological | 1 | 2015 | 1821 | 0.020 |
Why?
| | Leg | 1 | 2010 | 239 | 0.020 |
Why?
| | Angiotensins | 1 | 2007 | 8 | 0.020 |
Why?
| | Receptor, Angiotensin, Type 1 | 1 | 2007 | 25 | 0.020 |
Why?
| | Peptidyl-Dipeptidase A | 1 | 2007 | 56 | 0.020 |
Why?
| | Pancreatic Function Tests | 1 | 2005 | 3 | 0.010 |
Why?
| | Amino Acid Substitution | 1 | 2006 | 304 | 0.010 |
Why?
| | C-Peptide | 1 | 2005 | 189 | 0.010 |
Why?
| | Glucose Tolerance Test | 1 | 2005 | 361 | 0.010 |
Why?
| | Tomography, X-Ray Computed | 1 | 2014 | 2730 | 0.010 |
Why?
| | Mother-Child Relations | 1 | 2004 | 134 | 0.010 |
Why?
| | Population Surveillance | 1 | 2006 | 485 | 0.010 |
Why?
| | Endothelium, Vascular | 1 | 2008 | 965 | 0.010 |
Why?
| | Oxidative Stress | 1 | 2006 | 1339 | 0.010 |
Why?
| | DNA | 1 | 2006 | 1463 | 0.010 |
Why?
| | Pregnancy | 1 | 2006 | 7190 | 0.010 |
Why?
|
|
Wadwa's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|